The global viral vector & plasmid DNA manufacturing market is expected to reach a value of above US$ 2 Bn by the end of 2027, expanding at a high double digit CAGR during the forecast period. Increase in prevalence and incidence rates of cancer, genetic disorders and infectious diseases, high unmet needs in patients with rare disorders, and raised acceptance for comparatively newer treatment options in developing countries are expected to boost the viral vector & plasmid DNA manufacturing market during the forecast period. According to Cancer Research UK, there were 17 million new cases of cancer in 2018 and four most common types of cancer worldwide are breast, lung, bowel, and prostate cancers, which account for approximately 43% of all new cases.

The global viral vector & plasmid DNA manufacturing market has been segmented based on type, application, disease, end-user, and region. In terms of type, the global market has been classified into lentivirus, adenovirus, adeno-associated virus (AAV), plasmid DNA, and others. The plasmid DNA segment dominates the viral vector & plasmid DNA manufacturing market, in terms of value. Increasing acceptance of viral vector-based advanced treatments is likely to drive the segment. The adeno-associated virus (AAV) segment is also expected to expand at a significant CAGR during the forecast period. This is primarily attributed to the wide use of AAV as vector of choice in variety of clinical trials ongoing worldwide.

Get Sample Papers of the Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30428

In terms of disease, the global market has been divided into genetic disorders, cancer, infectious disease, and others. The cancer segment dominates the viral vector & plasmid DNA manufacturing market, in terms of value. This is primarily attributed to aggressive research initiatives based on viral vector based products for the treatment of variety of cancer. The genetic disorders segment is expected to expand at a significant CAGR during the forecast period.

In terms of end-user, the viral vector & plasmid DNA manufacturing market has been segregated into biotech companies and research institutes. The biotech companies segment held a major share of the market, followed by the research institutes segment, in 2018. The biotech companies segment is expected to maintain its market share during the forecast period, due to increased demand for large-scale production of viral vectors and plasmid DNA for commercial use.

In terms of application, the global market has been classified into gene therapy, vaccinology, and others. The gene therapy segment dominates the viral vector & plasmid DNA manufacturing market, in terms of value. This is primarily attributed to the increasing acceptance of gene therapy products for the treatment of rare disorders across the globe and availability of approved gene therapy products. The vaccinology segment is expected to expand at a significant CAGR during the forecast period. The expansion is attributed to the increased research initiatives for viral vector based vaccines.

Get PDF Brochure of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30428

Major players operating in the viral vector & plasmid DNA manufacturing market include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies Inc., Spark Therapeutics, Inc. Merck KGaA, uniQure N.V., and Lonza. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical companies, which is expected to increase product availability, and thereby boost the market.

Leave a Reply

Your email address will not be published. Required fields are marked *